Lisata Therapeutics Inc

Lisata Therapeutics Inc maintains a strong liquidity position, with a current ratio of 8.92, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $21.81 million, which is a substantial portion of its total assets of $48.24 million. The absence of long-term debt further supports the company's liquidity profile, as it does not have any long-term debt obligations to service. The company's profitability metrics are currently negative, with a net income of -$5.40 million and an operating income of -$6.60 million. The return on equity (ROE) is -12.56%, and the return on assets (ROA) is -11.2%, both of which are below the typical thresholds for a profitable biotechnology firm. The price-to-book ratio of 0.65 suggests that the company's market value is trading at a discount to its book value, which may reflect the market's skepticism about the company's ability to generate positive returns in the near term. Lisata Therapeutics Inc does not disclose specific revenue by business segments or geographic regions in the provided data, making it difficult to assess the company's revenue concentration. However, the company's operations are likely focused on the United States, as is common for many biotechnology firms. The lack of detailed segment data limits the ability to evaluate the company's exposure to different markets or product lines. The company's growth trajectory is uncertain, as the provided data does not include historical revenue figures or forward-looking guidance. Analysts have provided a wide range of price targets, from $4.00 to $15.00, with a mean of $11.33 and a median of $15.00. The mean recommendation is 2.00, which is a "Buy" rating, but the absence of any "Strong Buy" ratings suggests a cautious outlook among analysts. The risk assessment for Lisata Therapeutics Inc indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces the risk of financial distress. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. Recent events related to Lisata Therapeutics Inc are not detailed in the provided data. The company has not filed any recent 10-K or 10-Q reports that would provide insight into its operations or strategic direction. The lack of recent filings may indicate that the company is in an early stage of development or that it is not currently required to file regular reports with the SEC.